Boswellia for osteoarthritis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00133973" target="_blank" >RIV/00216224:14110/22:00133973 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014969/full" target="_blank" >https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014969/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/14651858.CD014969" target="_blank" >10.1002/14651858.CD014969</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Boswellia for osteoarthritis

Popis výsledku v původním jazyce

Osteoarthritis (OA) is a common, chronic disorder of the joints that imparts a substantial and ever‐increasing health burden, especially in the elderly population (Cross 2014; Glyn‐Jones 2015). OA affects 7% of the global population and is responsible for 2% of total global years lived with disability (GBD 2020). OA prevalence is higher in women, and increases with advancing age and increasing body mass index (BMI (Palazzo 2016)). Due to the increasing prevalence of obesity and an ageing global population, the prevalence of OA has been steadily increasing over the past few decades (GBD 2020). OA is a leading cause of chronic pain and long‐term disability in adults; its major symptoms include joint pain, stiffness, and joint functional loss (Martel‐Pelletier 2016). OA most commonly affects the joints in the knees, hips, hand, foot, ankle, back, and neck (Kapoor 2015). The pathogenesis of OA is complex, and involves a dynamic process mediated by mechanical, inflammatory, and metabolic factors (Katz 2021; Mobasheri 2016). The current treatment guidelines for OA list few management options, which include non‐pharmacological and pharmacological options. Non‐pharmacological treatments are the core treatment option for the management of OA, and include weight loss, self‐management and education programmes, and physical exercise. Pharmacological treatments include oral nonsteroidal anti‐inflammatory drugs (NSAIDs) in those without contraindications, topical NSAIDs, and glucocorticoid injections (Bannuru 2019; Fransen 2015; Katz 2021; Messier 2013; Rini 2015). NSAIDs are often the first‐line pharmacologic treatment for OA; however, they are often contraindicated in people with OA, who often have comorbidities (Honvo 2019; Mason 2004; Rannou 2016).

Název v anglickém jazyce

Boswellia for osteoarthritis

Popis výsledku anglicky

Osteoarthritis (OA) is a common, chronic disorder of the joints that imparts a substantial and ever‐increasing health burden, especially in the elderly population (Cross 2014; Glyn‐Jones 2015). OA affects 7% of the global population and is responsible for 2% of total global years lived with disability (GBD 2020). OA prevalence is higher in women, and increases with advancing age and increasing body mass index (BMI (Palazzo 2016)). Due to the increasing prevalence of obesity and an ageing global population, the prevalence of OA has been steadily increasing over the past few decades (GBD 2020). OA is a leading cause of chronic pain and long‐term disability in adults; its major symptoms include joint pain, stiffness, and joint functional loss (Martel‐Pelletier 2016). OA most commonly affects the joints in the knees, hips, hand, foot, ankle, back, and neck (Kapoor 2015). The pathogenesis of OA is complex, and involves a dynamic process mediated by mechanical, inflammatory, and metabolic factors (Katz 2021; Mobasheri 2016). The current treatment guidelines for OA list few management options, which include non‐pharmacological and pharmacological options. Non‐pharmacological treatments are the core treatment option for the management of OA, and include weight loss, self‐management and education programmes, and physical exercise. Pharmacological treatments include oral nonsteroidal anti‐inflammatory drugs (NSAIDs) in those without contraindications, topical NSAIDs, and glucocorticoid injections (Bannuru 2019; Fransen 2015; Katz 2021; Messier 2013; Rini 2015). NSAIDs are often the first‐line pharmacologic treatment for OA; however, they are often contraindicated in people with OA, who often have comorbidities (Honvo 2019; Mason 2004; Rannou 2016).

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

<a href="/cs/project/EF18_053%2F0016952" target="_blank" >EF18_053/0016952: Postdoc2MUNI</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cochrane Database of Systematic Reviews

ISSN

1469-493X

e-ISSN

1361-6137

Svazek periodika

10

Číslo periodika v rámci svazku

October 2022

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

14

Strana od-do

1-14

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85140243062